Causal Links Between Antibody-Mediated Immune Responses and Pancreatic Cancer Risk
Open Access
- 25 August 2026
- journal article
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 26, 1-10
Abstract
Introduction: Pancreatic cancer (PC) presents unique challenges to traditional immunotherapy due to its immunosuppressive microenvironment and low mutation burden. Research into antibody-mediated immune responses, which has been extensively applied in various cancer types, is also applicable to the study of pancreatic cancer. Methods: Using public Genome-wide association study (GWAS) data and genetic instruments, we conducted a two-sample Mendelian randomization (MR) analysis to explore causal relationships between 46 antibody-mediated immune responses and PC. We employed five MR methods. Cochran’s Q statistic and corresponding p-values from the MR Egger and Inverse Variance Weighted methods assessed instrument heterogeneity. Egger intercept and MR pleiotropy residual sum and outlier (MR-PRESSO) methods detected potential horizontal pleiotropy, ensuring the robustness of our findings. Results: Our study identified causal links between five antibody-mediated immune responses and pancreatic cancer risk. Chlamydia trachomatis momp A antibody levels were inversely correlated, while Anti-helicobacter pylori IgG seropositivity, Polyomavirus 2 JC VP1 antibody levels, and Merkel cell polyomavirus VP1 antibody levels showed positive correlations. Notably, Anti- Merkel cell polyomavirus IgG seropositivity exhibited strong positive associations across Inverse variance weighting (IVW), weighted median, and MR-Egger analyses (p < 0.05). Discussion: These results suggest that specific Antibody-Mediated Immune Responses may modulate pancreatic carcinogenesis through immune activation or chronic inflammation. The protective association for Chlamydia trachomatis momp A contrasts with the risk-enhancing effects observed for anti-helicobacter pylori IgG and polyomaviruses, highlighting heterogeneous immunobiological pathways that warrant mechanistic investigation. Conclusion: Our study demonstrated a randomized causal effect between antibody-mediated immune responses and pancreatic cancer, offering a new perspective for clinical diagnosis and treatment of the disease.Keywords
This publication has 71 references indexed in Scilit:
- Causal association of antibody-mediated immune responses to infectious disease agents with lung cancer: a Mendelian randomization studyDiscover Oncology, 2025
- Unveiling the immunological terrain of pancreatic ductal adenocarcinoma: strategies to prompt immunotherapy from Mendelian randomizationDiscover Oncology, 2025
- Revisiting JC virus and progressive multifocal leukoencephalopathyJournal of NeuroVirology, 2023
- Unlocking the Power of Complement-Dependent Cytotoxicity: Engineering Strategies for the Development of Potent Therapeutic Antibodies for Cancer TreatmentsBioDrugs, 2023
- Pancreatic cancer: Advances and challengesCell, 2023
- Causal factors underlying diabetes risk informed by Mendelian randomisation analysis: evidence, opportunities and challengesDiabetologia, 2023
- Exploring and mitigating potential bias when genetic instrumental variables are associated with multiple non-exposure traits in Mendelian randomizationEuropean Journal of Epidemiology, 2022
- Tumor-reactive antibodies evolve from non-binding and autoreactive precursorsCell, 2022
- Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohortInternational Journal of Cancer, 2020
- Mendelian RandomizationJAMA, 2017